Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs, specifically in endocrine conditions and neurodegenerative diseases. The company's core business model revolves around the research, development, and potential commercialization of investigational therapies, generating revenue primarily through product sales if regulatory approvals are obtained. The company recently ceased marketing and selling its previous commercial product, RELYVRIO/ALBRIOZA for ALS, in the U.S. and Canada, and therefore expects to generate significant losses for the foreseeable future ¹.

The company's pipeline includes several investigational assets. Avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is being evaluated for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (Congenital HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both PBH and HI, Rare Pediatric Disease Designation in Congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia ². PBH is estimated to affect approximately 8% of people in the U.S. who have undergone sleeve gastrectomy and Roux-en-Y gastric bypass, totaling approximately 160,000 people ³. There are currently no approved therapies for PBH ⁴. Avexitide works by binding to the GLP-1 receptor on pancreatic islet beta cells to inhibit GLP-1's effect, thereby decreasing insulin secretion and stabilizing blood glucose levels ⁵. The LUCIDITY (NCT06747468) trial is an approximately 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating avexitide in PBH following RYGB surgery ⁶. Recruitment for LUCIDITY is complete, with topline data expected in Q3 2026 and a potential commercial launch in 2027 ⁷. Previous Phase 2 trials (PREVENT and Phase 2b) showed significant reductions in Level 2 and 3 hypoglycemic events and a favorable safety profile ⁸.

Another key asset is AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, which is being investigated for Wolfram syndrome. This neurodegenerative disease affects approximately 3,000 people in the U.S. and more worldwide, with no approved therapies currently available ⁹. AMX0035 is hypothesized to mitigate cell death by reducing endoplasmic reticulum (ER) stress and mitochondrial dysfunction ¹⁰. Positive Week 48 data from the Phase 2 open-label HELIOS (NCT05676034) clinical trial in 12 adults with Wolfram syndrome demonstrated continued and sustained improvement in pancreatic beta cell function, glycemic control, and visual acuity ¹¹. The safety profile was consistent with prior data, with all adverse events being mild or moderate and no serious adverse events related to AMX0035 treatment ¹². The company is working with the FDA on a Phase 3 trial for Wolfram syndrome ¹³.

The pipeline also includes AMX0114, an investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2) for amyotrophic lateral sclerosis (ALS). ALS is a rare, progressive, and fatal neurodegenerative disorder affecting up to 30,000 adults in the U.S. and 3,000 in Canada ¹⁴. The Phase 1 LUMINA clinical trial (NCT06665165) for AMX0114 in ALS dosed its first participant in April 2025 ¹⁵. Cohort 1 (n=12) was fully enrolled in September 2025, and Cohort 2 (n=12) enrollment began in December 2025, with initial safety data from Cohort 1 showing AMX0114 was generally well-tolerated with no treatment-related serious adverse events ¹⁶. Cohort 1 biomarker data is expected in the first half of 2026 ¹⁷. Lastly, AMX0318, a novel GLP-1 receptor antagonist for long-acting administration, was selected as a development candidate for PBH and other rare diseases in January 2026 ¹⁸. IND-enabling studies are underway, with an Investigational New Drug (IND) application targeted for 2027 ¹⁹.

For the fiscal year ended December 31, 2025, the company reported an accumulated deficit of $751.4 million ²⁰. The company generated revenues of $380.8 million in 2023 from sales of RELYVRIO/ALBRIOZA, but will no longer generate revenue from this product following its withdrawal ²¹. The company's patent estate as of December 31, 2025, included 23 issued U.S. patents, 257 granted foreign patents, over 15 pending U.S. patent applications, and over 115 pending foreign patent applications ²². The company acquired the avexitide patent portfolio from Eiger Pharmaceuticals, Inc. in July 2024 ²³.

The company anticipates significant expenses for the foreseeable future as it continues the clinical development of avexitide, AMX0035 in indications other than ALS, and for the preclinical and clinical development of additional product candidates, including AMX0114 and AMX0318 ²⁴. The company believes its existing cash, cash equivalents, and marketable securities as of December 31, 2025, will be sufficient to fund operations into 2028 ²⁵. However, this estimate may prove incorrect, and additional funds may be needed sooner than anticipated due to changing circumstances ²⁶.

A major growth area is the potential commercialization of avexitide for post-bariatric hypoglycemia (PBH). The Phase 3 LUCIDITY trial for avexitide in PBH has completed recruitment, with randomization and dosing of the last eligible patients expected in Q1 2026 ²⁷. Topline data from this trial is anticipated in Q3 2026, and if approved, a commercial launch is projected for 2027 ²⁸. Avexitide has received Breakthrough Therapy Designation for PBH and Orphan Drug Designation for hyperinsulinemic hypoglycemia, which includes PBH ²⁹. The market for PBH is estimated to affect approximately 160,000 people in the U.S. ³⁰, and there are currently no approved therapies ³¹, presenting a significant unmet medical need.

Another key growth vector is the development of AMX0035 for Wolfram syndrome. Positive Week 48 data from the Phase 2 HELIOS trial showed sustained improvements or stabilization in pancreatic beta cell function, glycemic control, and visual acuity in adults with Wolfram syndrome ³². The company is actively working with the FDA on a Phase 3 trial for this indication ³³. Wolfram syndrome is a rare neurodegenerative disease affecting approximately 3,000 people in the U.S. ³⁴, and AMX0035 has received Orphan Drug Designation for its treatment ³⁵. The company also plans to provide clinical trial supply of AMX0035 for an externally-sponsored trial investigating it as adjunctive therapy for insulin resistance in type 1 diabetes ³⁶.

The company is also advancing AMX0114 for ALS, with the Phase 1 LUMINA trial having dosed its first participant in April 2025 ³⁷. Cohort 1 (n=12) was fully enrolled in September 2025, and Cohort 2 (n=12) enrollment began in December 2025 ³⁸. Initial safety data from Cohort 1 demonstrated AMX0114 was generally well-tolerated with no treatment-related serious adverse events ³⁹. Cohort 1 biomarker data is expected in the first half of 2026 ⁴⁰. AMX0114 has received Fast Track Designation for ALS ⁴¹. Furthermore, AMX0318, a novel GLP-1 receptor antagonist, was selected as a development candidate for PBH and other rare diseases in January 2026, with IND-enabling studies underway and an IND targeted for 2027 ⁴².

The company's operational outlook includes a continued reliance on third-party contract manufacturing organizations (CMOs) for the production of its product candidates in compliance with cGMP requirements for clinical trials and potential commercial supply ⁴³. The company has development and/or supply agreements in place for active pharmaceutical ingredients and for drug product manufacturing and packaging ⁴⁴. A team of pharmaceutical industry technical operations leaders oversees third-party manufacturers and maintains quality and regulatory compliance ⁴⁵. The company also maintains a Quality Management System consistent with a regulated industry ⁴⁶.

Planned capital allocation will focus on funding the clinical development of avexitide, AMX0035 for indications other than ALS, and the preclinical and clinical development of AMX0114 and AMX0318 ⁴⁷. The company may also pursue in-licensing or acquisition of other product candidates or technologies ⁴⁸. The number of shares reserved for issuance under the 2022 Stock Option and Incentive Plan will automatically increase on January 1 of each year through 2032 by 5.0% of the total shares outstanding on December 31 of the preceding year, or a lesser number determined by the board ⁴⁹. Similarly, shares reserved for the 2022 Employee Stock Purchase Plan will increase annually by the lesser of 1.0% of outstanding common stock or 1,210,000 shares ⁵⁰. The company currently plans to retain all future earnings to finance operations, development, and growth, and does not anticipate paying cash dividends in the foreseeable future ⁵¹.

Structural headwinds and execution risks include the inherent unpredictability and lengthy nature of regulatory approval processes, which can be delayed or denied for various reasons, including disagreement with data interpretation or requirements for additional studies ⁵². The company's historical concentration in neurodegenerative diseases, a field with limited product development success, and its recent expansion into endocrine and metabolic fields where it has limited experience, pose challenges ⁵³. The U.S. Supreme Court's July 2024 decision in Loper Bright Enterprises v. Raimondo, overturning the Chevron doctrine, introduces uncertainty regarding the FDA's regulations and policies, potentially leading to increased legal challenges and delays ⁵⁴. Geopolitical instability, ongoing military conflicts (e.g., Russia-Ukraine, Middle East), and evolving U.S. government regulatory activities and economic policies, including potential tariffs on pharmaceutical imports, could disrupt supply chains, increase costs, and negatively impact business operations ⁵⁵.

The company faces material risks including significant losses for the foreseeable future due to ceasing marketing and sales of its previous commercial product, RELYVRIO/ALBRIOZA, for ALS, and will not return to profitability until successful commercialization of current or future product candidates ⁵⁶. There is heavy dependence on the success of avexitide and AMX0035, with delays or failures in late-stage trials or regulatory approvals posing substantial harm ⁵⁷. The regulatory approval process is lengthy, time-consuming, and unpredictable, with potential for delays, denials, or withdrawals of approval, which could cause the company to delay or cease operations ⁵⁸. The markets for avexitide and AMX0035 in their target indications (PBH, Congenital HI, Wolfram syndrome) may be smaller than expected, impacting future revenues ⁵⁹. Product liability lawsuits are an inherent risk in pharmaceutical development and commercialization, potentially leading to substantial liabilities, diversion of resources, and limitations on commercialization, with current insurance coverage of up to $10.0 million in the aggregate potentially being inadequate ⁶⁰. Compliance with global privacy and data security requirements, including GDPR and evolving U.S. state laws, could result in additional costs and liabilities, with potential fines of up to 4% of annual global revenues or €20 million (£17.5 million under UK GDPR), whichever is greater, for GDPR violations ⁶¹. The use of new and evolving technologies, including artificial intelligence, presents cybersecurity, data privacy, intellectual property, regulatory, and reputational risks, with the EU Artificial Intelligence Act imposing significant obligations and potential fines for non-compliance ⁶². Changes in tax law, such as the OBBBA signed in July 2025, could adversely affect the business and financial condition, including changes to research and development expense deductions and Medicaid funding ⁶³. Unfavorable macroeconomic conditions, market volatility, geopolitical instability, and military conflicts could adversely affect business, financial condition, and results of operations, including supply chain disruptions and increased costs ⁶⁴.

Management emphasizes a mission to develop and advance novel therapies for communities with high unmet medical needs, focusing on preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. They highlight a pipeline where investigational therapies are matched with diseases based on mechanistic rationales, clear clinical outcomes, biomarkers, and rigorous preclinical data. A key strategic priority is the successful completion of the Phase 3 LUCIDITY clinical trial for avexitide in PBH, with expectations to randomize and dose the last eligible patients in Q1 2026, and anticipate topline data in Q3 2026, leading to a commercial launch in 2027 if approved ⁶⁵. Another priority is advancing AMX0035 in Wolfram syndrome, following positive Week 48 data from the Phase 2 HELIOS trial, and continuing discussions with the FDA on a Phase 3 trial ⁶⁶. The development of AMX0114 for ALS, with the Phase 1 LUMINA trial underway and Cohort 1 biomarker data expected in the first half of 2026, is also a strategic focus ⁶⁷. Management also stresses the importance of identifying and advancing additional product candidates, such as AMX0318, for which IND-enabling studies are underway with an IND targeted for 2027 ⁶⁸. The overall tone reflects a commitment to responsible operations, as evidenced by a formal ESG charter and a focus on diversity and inclusion within the workforce, with three of eight senior executives being women and two of seven board members being women ⁶⁹.